Penserra Capital Management LLC cut its position in abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 9.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 746,921 shares of the company's stock after selling 80,654 shares during the quarter. Penserra Capital Management LLC owned 2.59% of abrdn Life Sciences Investors worth $9,478,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in shares of abrdn Life Sciences Investors by 16.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 193,484 shares of the company's stock valued at $2,455,000 after buying an additional 27,433 shares in the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of abrdn Life Sciences Investors by 46.5% in the first quarter. Oppenheimer & Co. Inc. now owns 28,713 shares of the company's stock valued at $364,000 after buying an additional 9,115 shares in the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of abrdn Life Sciences Investors by 36.1% in the first quarter. Flagship Harbor Advisors LLC now owns 340,877 shares of the company's stock valued at $4,326,000 after buying an additional 90,436 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of abrdn Life Sciences Investors in the first quarter valued at $134,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in shares of abrdn Life Sciences Investors in the first quarter valued at $131,000. 32.21% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, major shareholder Saba Capital Management, L.P. sold 23,729 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $12.08, for a total transaction of $286,646.32. Following the completion of the transaction, the insider directly owned 3,028,958 shares of the company's stock, valued at $36,589,812.64. The trade was a 0.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 62,388 shares of company stock worth $752,056. Insiders own 10.06% of the company's stock.
abrdn Life Sciences Investors Trading Up 1.1%
HQL traded up $0.14 on Thursday, hitting $13.39. 120,235 shares of the company were exchanged, compared to its average volume of 107,901. abrdn Life Sciences Investors has a twelve month low of $10.55 and a twelve month high of $15.90. The firm has a 50-day moving average price of $12.61 and a two-hundred day moving average price of $12.93.
abrdn Life Sciences Investors Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Thursday, May 22nd were paid a dividend of $0.43 per share. The ex-dividend date was Thursday, May 22nd. This represents a $1.72 annualized dividend and a yield of 12.85%.
About abrdn Life Sciences Investors
(
Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Read More
Before you consider abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and abrdn Life Sciences Investors wasn't on the list.
While abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
